Navigation Links
Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
Date:4/18/2011

ANAHEIM, Calif., April 18, 2011 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release first quarter 2011 financial results on Tuesday, April 26, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and webcast on Tuesday, April 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the first quarter, as well as current corporate developments.  Conference call details:Date:

Tuesday, April 26, 2011Time:

4:30 p.m. ETDial-in (U.S.):

877-941-1465Dial-in (International):

480-629-9678Web cast:

www.questcor.comTo access an audio replay of the call:Replay (U.S.):

800-406-7325Replay (International):

303-590-3030Replay Passcode:

4434709About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
2. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
3. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
4. Questcor Pharmaceuticals Selects BDO USA as its Auditor
5. Questcor Reports 2010 Financial Results
6. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
7. Questcor Pharmaceuticals Reports Strong Finish to 2010
8. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
9. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Questcor to Present at the Maxim Group Growth Conference
11. Questcor Reports Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... June 1, 2017 Nutriceutical Holdings (NH), parent ... Solutions (VRS), and KD Pharma Group have decided to ... by KD Pharma Group. KD Pharma Group will become ... to acquire the entire company. "We believe ... are committed to growing the NH companies by providing ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
Breaking Medicine Technology:
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... , ... June 23, 2017 , ... By scoring 100% ... ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work ... 1% of all charities reviewed by Charity Navigator and earns ANRF a spot on ...
(Date:6/23/2017)... , ... June 24, 2017 , ... Studies show evidence ... reduce the risk of visual loss in these patients. , But how often do ... or smoking cessation to patients at risk of or with early symptoms of AMD? ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... plastic surgeon practicing in Newburgh, New York, has recently begun offering three new ... to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited ...
Breaking Medicine News(10 mins):